Clearside Biomedical Past Earnings Performance
Past criteria checks 0/6
Clearside Biomedical has been growing earnings at an average annual rate of 15.4%, while the Pharmaceuticals industry saw earnings declining at 0.4% annually. Revenues have been growing at an average rate of 19.1% per year.
Key information
15.4%
Earnings growth rate
35.3%
EPS growth rate
Pharmaceuticals Industry Growth | 6.0% |
Revenue growth rate | 19.1% |
Return on equity | n/a |
Net Margin | -413.7% |
Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Here's Why We're Watching Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation
Nov 06We're Keeping An Eye On Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Rate
Jun 24Here's Why We're Not At All Concerned With Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation
Nov 12Analyst Forecasts Just Became More Bearish On Clearside Biomedical, Inc. (NASDAQ:CLSD)
Aug 11Clearside Biomedical Q2 2022 Earnings Preview
Aug 08Clearside Biomedical: A Pivotal 2022 Ahead
Apr 13Clearside's Safety Data In Wet AMD And Emphasis On SCS Microinjector Make It Great Speculative Play
Dec 22Clearside Biomedical (NASDAQ:CLSD) Is In A Strong Position To Grow Its Business
Sep 30Clearside's Value Proposition Is Far From Clear
Aug 07We Think Clearside Biomedical (NASDAQ:CLSD) Can Easily Afford To Drive Business Growth
Jun 17Clearside Biomedical climbs after positive results from early-stage wet AMD trial
Jun 15Clearside Biomedical resubmits eye treatment XIPERE NDA
May 03If You Had Bought Clearside Biomedical (NASDAQ:CLSD) Shares A Year Ago You'd Have Earned 45% Returns
Feb 16Clearside Biomedical's early-stage wet AMD study gets underway
Jan 12Trade Alert: Bradford Whitmore At Clearside Biomedical, Inc. (NASDAQ:CLSD), Has Just Spent US$1m Buying 11% More Shares
Jan 12Clearside Bio drops 11% on launch of $12M direct offering
Jan 06Clearside Biomedical: SCS Microinjector Platform With Significant Upside
Jan 05Revenue & Expenses BreakdownBeta
How Clearside Biomedical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 8 | -35 | 12 | 22 |
31 Dec 23 | 8 | -32 | 12 | 21 |
30 Sep 23 | 2 | -37 | 12 | 20 |
30 Jun 23 | 2 | -36 | 12 | 19 |
31 Mar 23 | 1 | -35 | 11 | 20 |
31 Dec 22 | 1 | -33 | 12 | 20 |
30 Sep 22 | 27 | -5 | 12 | 18 |
30 Jun 22 | 29 | -2 | 12 | 19 |
31 Mar 22 | 30 | 0 | 12 | 18 |
31 Dec 21 | 30 | 0 | 12 | 19 |
30 Sep 21 | 4 | -25 | 11 | 19 |
30 Jun 21 | 4 | -23 | 11 | 18 |
31 Mar 21 | 4 | -23 | 11 | 17 |
31 Dec 20 | 8 | -18 | 11 | 15 |
30 Sep 20 | 10 | -14 | 12 | 12 |
30 Jun 20 | 7 | -18 | 13 | 9 |
31 Mar 20 | 6 | -18 | 16 | 9 |
31 Dec 19 | 2 | -31 | 17 | 16 |
30 Sep 19 | 0 | -49 | 17 | 32 |
30 Jun 19 | 0 | -67 | 17 | 52 |
31 Mar 19 | 0 | -82 | 16 | 66 |
31 Dec 18 | 0 | -83 | 15 | 68 |
30 Sep 18 | 0 | -78 | 13 | 65 |
30 Jun 18 | 0 | -72 | 11 | 61 |
31 Mar 18 | 0 | -65 | 10 | 55 |
31 Dec 17 | 0 | -59 | 10 | 49 |
30 Sep 17 | 0 | -52 | 10 | 42 |
30 Jun 17 | 0 | -39 | 9 | 30 |
31 Mar 17 | 0 | -31 | 8 | 22 |
31 Dec 16 | 1 | -26 | 6 | 19 |
30 Sep 16 | 1 | -21 | 5 | 16 |
30 Jun 16 | 1 | -19 | 5 | 15 |
31 Mar 16 | 1 | -19 | 7 | 13 |
31 Dec 15 | 0 | -18 | 7 | 11 |
30 Sep 15 | 0 | -15 | 6 | 9 |
30 Jun 15 | 0 | -15 | 6 | 9 |
31 Mar 15 | 0 | -12 | 4 | 8 |
31 Dec 14 | 0 | -10 | 3 | 7 |
30 Sep 14 | 0 | -9 | 3 | 6 |
30 Jun 14 | 0 | -8 | 3 | 5 |
31 Mar 14 | 0 | -8 | 2 | 5 |
Quality Earnings: CLSD is currently unprofitable.
Growing Profit Margin: CLSD is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CLSD is unprofitable, but has reduced losses over the past 5 years at a rate of 15.4% per year.
Accelerating Growth: Unable to compare CLSD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CLSD is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (11.7%).
Return on Equity
High ROE: CLSD's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.